Generation of large-scale mature, monocyte-derived dendritic cells from adult cancer patients for the development of dendritic cell anti-cancer immunotherapy.

Generation of large-scale mature, monocyte-derived dendritic cells from adult cancer patients for the development of dendritic cell anti-cancer immunotherapy. - Production of DCs from cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32620

Enrollment

Registered

2010-01-05

Start date

2010-01-05

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer carcinoma neoplasm

Interventions

1. 1. Het afnemen van 5 extra core biopten (ACO) of 2 extra FNA biopten tijdens een endo-echografie 2. Bloedafname van max. 25 ml voorafgaande aan de endo-echografie 3. Het plaatsen van een naald m

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: histologically confirmed PC/EAC karnofsky performance status >60% patient must be eligible to undergo leukapheresis (see inclusion criteria in protocol) patient must have signed written consent

Exclusion criteria

Exclusion criteria: infection with hepatitis B, hepatitis C, HIV, HTLV and/or T. Pallidum severe hyperbilirubinemia, leukopenia, anaemia (see exclusioncriteria in protocol) karnofsky performance status

Design outcomes

Primary

Measure	Time frame
1. To determine if the vaccine meets the following releasecriteria: sterility, maturation state, phenotype and migratory capacity of the DCs 2. Determination of the amount of functional DCs obtained from 1 leukapheresis 3. Determination of the immunopotency of the DC vaccines by performing an IFN* ELISPOT assay.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)